Showing 2801-2810 of 3172 results for "".
- Report: Prescription Dermatological Drug Market Exceeds 21 Billion Dollarshttps://practicaldermatology.com/news/report-prescription-dermatological-drug-market-exceeds-21-billion-dollars/2458870/The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options
- National Psoriasis Foundation Awards Half a Million Dollars in Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-half-a-million-dollars-in-fellowships/2458922/Eleven early-career physicians each received a one-year, $50,000 National Psoriasis Foundation Medical Dermatology Fellowship to study psoriasis and psoriatic arthritis. These fellowships will help increase the number of scientists studying
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- Hair Restoration Doctors Name Best Celebrity Hair, Meeting Convenes October 23https://practicaldermatology.com/news/20131010-hair_restoration_doctors_name_best_celebrity_hair_meeting_convenes_october_23/2459438/Singer/songwriter John Mayer and “Modern Family” star Sofia Vergara are the male and female celebrities with the most sought-after hair, according to results of the International Society of Hair Restoration Surgery (ISHRS) member survey released rec
- Intralesional Cemiplimab Shows High Pathologic Response in Early-Stage CSCChttps://practicaldermatology.com/news/intralesional-cemiplimab-shows-high-pathologic-response-in-early-stage-cscc/2485540/Low-dose intralesional cemiplimab produced high objective and pathologic response rates without treatment-limiting toxicity in patients with early-stage cutaneous squamous cell carcinoma (CSCC), according to “Intralesional Cemiplimab for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma
- Dr. Amy McMichael Highlights Breakthrough Alopecia Therapieshttps://practicaldermatology.com/news/dr-amy-mcmichael-highlights-breakthrough-alopecia-therapies/2485364/Anyone not using low-dose oral minoxidil yet has “missed the boat.” That was the message from Amy McMichael, MD, during her presentation on non-scarring hair loss at the 2026 Winter Clinical Dermatology Conference in Hawaii. Dr. McMichael, who before her presentation was named the conferen
- TYK2 Inhibitor ICP-332 Demonstrates Efficacy, Safety in ADhttps://practicaldermatology.com/news/tyk2-inhibitor-icp-332-demonstrates-efficacy-safety-in-ad/2485331/A novel oral TYK2 inhibitor, ICP-332, demonstrated favorable safety and promising efficacy in a recent phase 2 randomized clinical trial for moderate to severe atopic dermatitis (AD). Researchers for the double-blind, placebo-co
- Commentary Flags Risks in Minoxidil Use Among Older Adultshttps://practicaldermatology.com/news/commentary-flags-risks-in-minoxidil-use-among-older-adults/2485231/In a recent commentary published in the Journal of the American Academy of Dermatology, Funda Datli Yakaryilmaz, MD, and Dursun Turkmen, MD, raise concerns about safety monitoring for low-dose oral minoxidil (LDOM) in older
- Isotretinoin Slows Growth Rate in Teens, But Final Height Unchangedhttps://practicaldermatology.com/news/isotretinoin-slows-growth-rate-in-teens-but-final-height-unchanged/2484962/Adolescents treated with isotretinoin for acne may experience temporary reductions in height velocity, but the medication does not appear to impact final adult height, according to a new retrospective cohort study published in the
- Remibrutinib Outperforms Placebo in Chronic Spontaneous Urticaria Control: Studyhttps://practicaldermatology.com/news/remibrutinib-outperforms-placebo-in-chronic-spontaneous-urticaria-control-study/2484429/Remibrutinib showed rapid and sustained efficacy in adults with chronic spontaneous urticaria (CSU) in a pooled analysis of the phase 3 REMIX-1 and REMIX-2 studies. The multicenter, double-blind, placebo-controlled trials looke